Barclays’s Alaunos Therapeutics TCRT Stock Holding History

Barclays’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-3,946	Closed	-$3.17M	–	6969
2016 Q4	$3.17M	Buy	+3,946	New	+$3.56M	﹤0.01%	1743
2015 Q2	–	Sell	-3,401	Closed	-$5.1M	–	7194
2015 Q1	$5.1M	Buy	+3,401	New	+$5.04M	0.01%	1545

Other funds holding TCRT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

Barclays's TCRT Position: Q4 2025 in Review

Barclays sold out of Alaunos Therapeutics (TCRT) in Q4 2025, closing a stake of 50 shares — an estimated $121 sold.

Barclays first reported a position in TCRT in Q2 2013 and held it in 40 quarters. The position peaked at $5.59M in Q4 2013. 27 funds tracked by Wall St. Rank hold TCRT as of Q4 2025.

Barclays reported no remaining Alaunos Therapeutics position as of Q4 2025 after selling out during the quarter.
Barclays sold 50 Alaunos Therapeutics shares in Q4 2025, an estimated $121.
Barclays first reported a position in Alaunos Therapeutics in Q2 2013 and held it in 40 quarters.
Barclays's Alaunos Therapeutics position peaked at $5.59M in Q4 2013.
27 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2025.

Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.